secondary hyperparathyroidism / primary hyperparathyroidism / parathyroid carcinoma
Endocrinology · 2005–2005
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cinacalcet hydrochloride Treatment of secondary hyperparathyroidism in patients with end stage renal disease receiving dialysis. | Nov 2005 | Not recommended | no section in document |
What the PBS pays
$1M in government benefit over 2024–25, across 32,858 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| cinacalcet hydrochloride | $1.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.